[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-stage-i\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-stage-i":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":43},"100548694","a-registry-for-people-with-lung-cancer-100548694",false,"NCT06424327","A Registry for People With Lung Cancer","Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology\n\nExclusion Criteria:\n\n* Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years\n* History of chemotherapy or radiation therapy for a previous lung cancer\n* Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery\n* Carcinoid tumors\n* History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix\n* Actively receiving treatment for other malignancies\n* Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.\n\n  * Multi-segmental resection from the same lobe is not a criterion for exclusion.","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.",[24,25],"Lung Cancer","Lung Cancer Stage I",[27,28,29,30,31],"lung cancer","lung cancer stage 1","segmentectomy","Memorial Sloan Kettering Cancer Center","24-127","RECRUITING","2026-05-29",{"date":35,"type":36},"2026-06-01","ACTUAL",{"date":38,"type":36},"2024-05-15",{"date":40,"type":20},"2029-05-15",{"name":30,"class":42},"OTHER",17,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100460869","avecure-flexible-microwave-ablation-probe-for-lung-nodules-100460869","NCT05281237","Avecure Flexible Microwave Ablation Probe For Lung Nodules","Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule","Inclusion Criteria:\n\n* Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.\n* Pathological proof of target nodule\u002Ftumor type and malignancy with specimen considered adequate per institutional laboratory standards\n* Target nodule\u002Ftumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively\n* Resection\u002Fsurgical candidate (lobectomy or greater)\n* Participants must be at least 22 years old and able to provide consent\n\nExclusion Criteria:\n\n* Subjects in whom flexible bronchoscopy is contraindicated\n* Target nodule \\\u003C 1.0 cm\n* Prior radiation or neo adjuvant chemotherapy of the target nodule\u002Ftumor\n* Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives\n* Pacemaker, implantable cardioverter, or another electronic implantable device\n* Patient cannot tolerate bronchoscopy\n* Patients with coagulopathy\n* Patients in other therapeutic lung cancer studies\n* Subject is pregnant or breastfeeding\n* COVID-19 positive patient at the time of procedure.","22 Years",{"count":53,"type":20},10,"INTERVENTIONAL",[56],"NA","This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size.\n\nThis research study involves microwave ablation (MWA)",[59,60,61,25,62,24],"Stage I - II Primary Lung Cancer","Stage I Lung Cancer","Stage II Lung Cancer","Lung Cancer Stage II",[64,60,61,25,62,24],"Stage I - II primary lung cancer","2026-04-07",{"date":67,"type":36},"2026-04-08",{"date":69,"type":36},"2022-06-01",{"date":71,"type":20},"2027-06-30",{"name":73,"class":42},"Beth Israel Deaconess Medical Center",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":54,"phases":83,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":74},"100308072","phase-2-feasibility-study-to-treat-lung-cancer-with-the-permanently-implantable-ldr-civasheet-100308072","NCT03290534","Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®","Inclusion Criteria:\n\n* Subject signed inform consent\n* Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left or right lung\n* Pre-operative criteria\n* Lung nodule suspicious for NSCLC\n* Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen\n* Clinical stage I or Clinical stage II\n* Not pregnant or nursing\n* Negative pregnancy test in premenopausal women\n* Fertile patients must use effective contraception\n* More than 5 years since prior invasive malignancy unless non melanoma skin cancer or in-situ cancer\n\nExclusion Criteria:\n\n\\-",{"count":82,"type":20},40,[84],"PHASE2","This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.",[24,25,62],[88,89,90,91,92,93,27,94],"wedge resection","sublobar resection","brachytherapy","CivaSheet","Pd-103","CivaTech Oncology","lung","2025-04-02",{"date":97,"type":36},"2025-04-04",{"date":99,"type":36},"2019-03-13",{"date":101,"type":20},"2027-12",{"name":93,"class":103},"INDUSTRY"]